PMID- 26165399
OWN - NLM
STAT- MEDLINE
DCOM- 20160808
LR  - 20230104
IS  - 2213-8595 (Electronic)
IS  - 2213-8587 (Linking)
VI  - 3
IP  - 11
DP  - 2015 Nov
TI  - Challenges and controversies in management of pancreatic neuroendocrine tumours 
      in patients with MEN1.
PG  - 895-905
LID - S2213-8587(15)00043-1 [pii]
LID - 10.1016/S2213-8587(15)00043-1 [doi]
AB  - Multiple endocrine neoplasia type 1 (MEN1), an autosomal dominant disorder, is 
      characterised by the occurrence of pancreatic neuroendocrine tumours (P-NETs) in 
      association with parathyroid and pituitary tumours. P-NETs, which include 
      gastrinomas, insulinomas, and non-functioning tumours, occur in more than 80% of 
      MEN1 patients and account for 50% of disease-specific deaths. However, there is 
      no consensus about the optimal methods for detecting and treating P-NETs in MEN1 
      patients, and extrapolations from approaches used in patients with non-familial 
      (sporadic) P-NETs require caution because of differences, such as the younger age 
      of onset, multi-focality of P-NETs, and concomitant presence of other tumours in 
      MEN1 patients. Thus, the early detection of P-NETs by circulating biomarkers and 
      imaging modalities, and their appropriate treatments by surgical approaches 
      and/or radionuclide therapy, chemotherapy, and biotherapy pose challenges and 
      controversies. These challenges and controversies will be reviewed and possible 
      approaches proposed.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Yates, Christopher J
AU  - Yates CJ
AD  - Academic Endocrine Unit, Radcliffe Department of Clinical Medicine, University of 
      Oxford, Oxford, UK; Department of Diabetes and Endocrinology, Melbourne Health, 
      Melbourne, VIC, Australia; Department of Diabetes and Endocrinology, Western 
      Health, Melbourne, VIC, Australia; Department of Medicine, University of 
      Melbourne, Melbourne, VIC, Australia.
FAU - Newey, Paul J
AU  - Newey PJ
AD  - Academic Endocrine Unit, Radcliffe Department of Clinical Medicine, University of 
      Oxford, Oxford, UK; Division of Cardiovascular and Diabetes Medicine, Ninewells 
      Hospital and Medical School, University of Dundee, Dundee, UK.
FAU - Thakker, Rajesh V
AU  - Thakker RV
AD  - Academic Endocrine Unit, Radcliffe Department of Clinical Medicine, University of 
      Oxford, Oxford, UK. Electronic address: rajesh.thakker@ndm.ox.ac.uk.
LA  - eng
GR  - G1000467/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150709
PL  - England
TA  - Lancet Diabetes Endocrinol
JT  - The lancet. Diabetes & endocrinology
JID - 101618821
RN  - 0 (Biomarkers)
SB  - IM
MH  - Biomarkers
MH  - Disease Management
MH  - Humans
MH  - Multiple Endocrine Neoplasia Type 1/complications/*diagnosis/*therapy
MH  - Neuroendocrine Tumors/complications/*diagnosis/*therapy
MH  - Pancreatic Neoplasms/complications/*diagnosis/*therapy
MH  - Treatment Outcome
EDAT- 2015/07/15 06:00
MHDA- 2016/08/09 06:00
CRDT- 2015/07/14 06:00
PHST- 2014/11/26 00:00 [received]
PHST- 2015/03/03 00:00 [accepted]
PHST- 2015/07/14 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2016/08/09 06:00 [medline]
AID - S2213-8587(15)00043-1 [pii]
AID - 10.1016/S2213-8587(15)00043-1 [doi]
PST - ppublish
SO  - Lancet Diabetes Endocrinol. 2015 Nov;3(11):895-905. doi: 
      10.1016/S2213-8587(15)00043-1. Epub 2015 Jul 9.